retatrutide parkinson clinical trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II retatrutide parkinson clinical trial retatrutide

GLP-1 agonists: With animal studies, there have been concerns of thyroid issues, including cancer, from using GLP-1 agonists

Women with a history of depression, anxiety, or mental health challenges should ensure their prescribing doctor is aware of this ongoing investigation and that their mental health is being monitored throughout treatment

See site for black box warnings and risk information

Press release: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill ) at ObesityWeek 2025, including demonstrated reductions in cardiovascular risk factors.* Retrieved from Rosenstock, J., Hsia, S., Ruiz, L